Abstract: Objective To systemically evaluate the efficacy and safety of oxaliplatin （OXA）based systemic chemotherapy regimens for advanced primary hepatic carcinoma，mainly hepatocellular carcinoma（HCC）. Methods The original articles were searched from PubMed，the Cochrane Library，EMBASE，Web of Science，CNKI，CBM and CECDB from inception to April 2015.Then we recruited the articles about OXA-based chemotherapy regimens for HCC，and evaluated the quality of literature. Finally we carried out a meta analysis of the eligible articles using Stata12.0. Results Twelve study reports， including 600 patients were recruited in this study. The results of meta analysis showed that OXAbased chemotherapy regimens had certain curative effect on advanced HCC patients. The overall response rate（RR）was 14.0 ％（95％CI：9.5％185％）. The median progression free survival （PFS）／median overall survival（OS）was 4.7／9.5 months，with 1 year progression free survival rate／1 year survival rate were 19.0％／35.6％. The common moderate-severe （grade 3／4） toxicities were neutropenia （16.6％）， thrombocytopenia （8.7％）， anemia （5.4％），neurotoxicity（4.9％），nausea／vomiting （1.8％） and diarrhea （2.9％）. In the subgroup analysis，RR of Asian and Western patients were 13.9％ （95％CI：8.1%-19.7％） and 14.2％（95％CI：5.3％-23.1％）respectively. In Asian studies，the median PFS/median OS and 1 year progression free survival rate／1 year survival rate were 3.0／9.4 months and 12.9％／30.3％ respectively. In Western studies， median PFS／OS and 1 year progression free survival rate／1 year survival rate were 4.7 months／9.5 months and 20.0％／42.4％ respectively. RR，1 year progression free survival rate and 1 year survival rate of OXA-based systemic chemotherapy regimens for advanced HCC had no significant difference（P＞0.05） between Asian and Western patients. Conclusion OXA-based systemic chemotherapy regimens are effective and safe for advanced HCC. It indicates that OXAbased systemic chemotherapy is a good and viable option for patients with advanced HCC.